Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

Interferon beta‐lb in the treatment of multiple sclerosis

1995 • 899 citations

PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS

2001 • 563 citations

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

2001 • 471 citations

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

2003 • 370 citations

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

1996 • 361 citations

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998 • 332 citations

A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS

2002 • 224 citations

Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

2000 • 223 citations

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies

1999 • 194 citations

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory

2002 • 149 citations

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b

1999 • 135 citations

The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction Unit

2001 • 119 citations

Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

2003 • 108 citations

Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

2000 • 96 citations

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

2001 • 94 citations

The clinical impact of interferon beta antibodies in relapsing-remitting MS

2004 • 93 citations

Parkinsonian signs in older people

2003 • 93 citations

Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification

2001 • 88 citations

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

2004 • 86 citations

A comparative study of the relative bioavailability of different interferon beta preparations

2000 • 86 citations

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

2003 • 62 citations

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients

2001 • 62 citations

Anti-IFN BAb and NAb antibodies

2003 • 49 citations

Neuronal Classes in the Isocortex of a Monotreme, the Australian Echidna <i>(Tachyglossus aculeatus)</i>

2003 • 35 citations

Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action

1997 • 33 citations

The expression of potency of neutralizing antibodies for interferons and other cytokines

1997 • 31 citations

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis

2000 • 28 citations